{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:56:56Z","timestamp":1789124216033,"version":"build-2803163510"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,11,5]],"date-time":"2013-11-05T00:00:00Z","timestamp":1383609600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s11899-013-0184-z","type":"journal-article","created":{"date-parts":[[2013,11,4]],"date-time":"2013-11-04T09:07:30Z","timestamp":1383556050000},"page":"299-306","source":"Crossref","is-referenced-by-count":14,"title":["Genetic Basis of MPN: Beyond JAK2-V617F"],"prefix":"10.1007","volume":"8","author":[{"given":"Nicole C. C.","family":"Them","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kralovics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,5]]},"reference":[{"key":"184_CR1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937\u201351.","journal-title":"Blood"},{"key":"184_CR2","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","volume":"105","author":"RA Mesa","year":"2005","unstructured":"Mesa RA, Li CY, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105:973\u20137.","journal-title":"Blood"},{"key":"184_CR3","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00277-009-0899-z","volume":"89","author":"E Crisa","year":"2010","unstructured":"Crisa E, Venturino E, Passera R, et al. A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs. Ann Hematol. 2010;89:691\u20139.","journal-title":"Ann Hematol"},{"key":"184_CR4","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29:3179\u201384.","journal-title":"J Clin Oncol"},{"key":"184_CR5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29:573\u201382.","journal-title":"J Clin Oncol"},{"key":"184_CR6","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054\u201361.","journal-title":"Lancet"},{"key":"184_CR7","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144\u20138.","journal-title":"Nature"},{"key":"184_CR8","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779\u201390.","journal-title":"N Engl J Med"},{"key":"184_CR9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387\u201397.","journal-title":"Cancer Cell"},{"issue":"Suppl 3","key":"184_CR10","doi-asserted-by":"crossref","first-page":"S329","DOI":"10.3816\/CLM.2009.s.032","volume":"9","author":"I Plo","year":"2009","unstructured":"Plo I, Vainchenker W. Molecular and genetic bases of myeloproliferative disorders: questions and perspectives. Clin Lymphoma Myeloma. 2009;9 Suppl 3:S329\u201339.","journal-title":"Clin Lymphoma Myeloma"},{"key":"184_CR11","doi-asserted-by":"crossref","first-page":"47954","DOI":"10.1074\/jbc.M205156200","volume":"277","author":"P Saharinen","year":"2002","unstructured":"Saharinen P, Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem. 2002;277:47954\u201363.","journal-title":"J Biol Chem"},{"key":"184_CR12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/protein\/14.1.27","volume":"14","author":"K Lindauer","year":"2001","unstructured":"Lindauer K, Loerting T, Liedl KR, Kroemer RT. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng. 2001;14:27\u201337.","journal-title":"Protein Eng"},{"key":"184_CR13","doi-asserted-by":"crossref","first-page":"18962","DOI":"10.1073\/pnas.0509714102","volume":"102","author":"X Lu","year":"2005","unstructured":"Lu X, Levine R, Tong W, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A. 2005;102:18962\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"184_CR14","doi-asserted-by":"crossref","first-page":"6724","DOI":"10.1038\/sj.onc.1210757","volume":"26","author":"SJ Baker","year":"2007","unstructured":"Baker SJ, Rane SG, Reddy EP. Hematopoietic cytokine receptor signaling. Oncogene. 2007;26:6724\u201337.","journal-title":"Oncogene"},{"key":"184_CR15","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"LM Scott","year":"2007","unstructured":"Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459\u201368.","journal-title":"N Engl J Med"},{"key":"184_CR16","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nature08448","volume":"461","author":"MA Dawson","year":"2009","unstructured":"Dawson MA, Bannister AJ, Gottgens B, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature. 2009;461:819\u201322.","journal-title":"Nature"},{"key":"184_CR17","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccr.2010.12.020","volume":"19","author":"F Liu","year":"2011","unstructured":"Liu F, Zhao X, Perna F, et al. JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell. 2011;19:283\u201394.","journal-title":"Cancer Cell"},{"key":"184_CR18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1242\/dmm.006817","volume":"4","author":"J Li","year":"2011","unstructured":"Li J, Kent DG, Chen E, Green AR. Mouse models of myeloproliferative neoplasms: JAK of all grades. Dis Model Mech. 2011;4:311\u20137.","journal-title":"Dis Model Mech"},{"key":"184_CR19","doi-asserted-by":"crossref","first-page":"9017","DOI":"10.1016\/S0021-9258(18)32158-6","volume":"258","author":"NA Nicola","year":"1983","unstructured":"Nicola NA, Metcalf D, Matsumoto M, Johnson GR. Purification of a factor inducing differentiation in murine myelomonocytic leukemia cells. Identification as granulocyte colony-stimulating factor. J Biol Chem. 1983;258:9017\u201323.","journal-title":"J Biol Chem"},{"key":"184_CR20","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1113\/jphysiol.2010.195057","volume":"589","author":"W Jelkmann","year":"2011","unstructured":"Jelkmann W. Regulation of erythropoietin production. J Physiol. 2011;589:1251\u20138.","journal-title":"J Physiol"},{"key":"184_CR21","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/369568a0","volume":"369","author":"K Kaushansky","year":"1994","unstructured":"Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 1994;369:568\u201371.","journal-title":"Nature"},{"key":"184_CR22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/08977190410001720851","volume":"22","author":"B Fishley","year":"2004","unstructured":"Fishley B, Alexander WS. Thrombopoietin signalling in physiology and disease. Growth Factors. 2004;22:151\u20135.","journal-title":"Growth Factors"},{"key":"184_CR23","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","volume":"108","author":"AD Pardanani","year":"2006","unstructured":"Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472\u20136.","journal-title":"Blood"},{"key":"184_CR24","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3324\/haematol.2010.034793","volume":"96","author":"D Pietra","year":"2011","unstructured":"Pietra D, Brisci A, Rumi E, et al. Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. Haematologica. 2011;96:607\u201311.","journal-title":"Haematologica"},{"key":"184_CR25","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1182\/blood-2004-10-4093","volume":"105","author":"W Tong","year":"2005","unstructured":"Tong W, Zhang J, Lodish HF. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood. 2005;105:4604\u201312.","journal-title":"Blood"},{"key":"184_CR26","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1084\/jem.20040762","volume":"200","author":"W Tong","year":"2004","unstructured":"Tong W, Lodish HF. Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis. J Exp Med. 2004;200:569\u201380.","journal-title":"J Exp Med"},{"key":"184_CR27","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood-2010-02-270108","volume":"116","author":"ST Oh","year":"2010","unstructured":"Oh ST, Simonds EF, Jones C, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood. 2010;116:988\u201392.","journal-title":"Blood"},{"key":"184_CR28","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMc1006966","volume":"363","author":"TL Lasho","year":"2010","unstructured":"Lasho TL, Pardanani A, Tefferi A. LNK mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med. 2010;363:1189\u201390.","journal-title":"N Engl J Med"},{"issue":"Pt 16","key":"184_CR29","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1242\/jcs.113.16.2813","volume":"113","author":"DL Krebs","year":"2000","unstructured":"Krebs DL, Hilton DJ. SOCS: physiological suppressors of cytokine signaling. J Cell Sci. 2000;113(Pt 16):2813\u20139.","journal-title":"J Cell Sci"},{"key":"184_CR30","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/sj.leu.2404513","volume":"21","author":"E Jost","year":"2007","unstructured":"Jost E, do ON, Dahl E, et al. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR\/ABL-negative myeloproliferative disorders. Leukemia. 2007;21:505\u201310.","journal-title":"Leukemia"},{"key":"184_CR31","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/ijc.23694","volume":"123","author":"L Teofili","year":"2008","unstructured":"Teofili L, Martini M, Cenci T, et al. Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. Int J Cancer. 2008;123:1586\u201392.","journal-title":"Int J Cancer"},{"key":"184_CR32","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1365-2141.2009.07860.x","volume":"147","author":"Y Suessmuth","year":"2009","unstructured":"Suessmuth Y, Elliott J, Percy MJ, et al. A new polycythaemia vera-associated SOCS3 SH2 mutant (SOCS3F136L) cannot regulate erythropoietin responses. Br J Haematol. 2009;147:450\u20138.","journal-title":"Br J Haematol"},{"key":"184_CR33","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nrm1762","volume":"6","author":"MH Schmidt","year":"2005","unstructured":"Schmidt MH, Dikic I. The Cbl interactome and its functions. Nat Rev Mol Cell Biol. 2005;6:907\u201318.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"184_CR34","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1182\/blood-2009-06-227033","volume":"115","author":"SJ Saur","year":"2010","unstructured":"Saur SJ, Sangkhae V, Geddis AE, et al. Ubiquitination and degradation of the thrombopoietin receptor c-Mpl. Blood. 2010;115:1254\u201363.","journal-title":"Blood"},{"key":"184_CR35","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","volume":"113","author":"FH Grand","year":"2009","unstructured":"Grand FH, Hidalgo-Curtis CE, Ernst T, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood. 2009;113:6182\u201392.","journal-title":"Blood"},{"key":"184_CR36","doi-asserted-by":"crossref","first-page":"10349","DOI":"10.1158\/0008-5472.CAN-08-2754","volume":"68","author":"AJ Dunbar","year":"2008","unstructured":"Dunbar AJ, Gondek LP, O'Keefe CL, et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res. 2008;68:10349\u201357.","journal-title":"Cancer Res"},{"key":"184_CR37","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","volume":"115","author":"PA Beer","year":"2010","unstructured":"Beer PA, Delhommeau F, LeCouedic JP, et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood. 2010;115:2891\u2013900.","journal-title":"Blood"},{"key":"184_CR38","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3324\/haematol.2009.013623","volume":"95","author":"F Stegelmann","year":"2010","unstructured":"Stegelmann F, Bullinger L, Griesshammer M, et al. High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrations. Haematologica. 2010;95:666\u20139.","journal-title":"Haematologica"},{"key":"184_CR39","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","volume":"478","author":"K Yoshida","year":"2011","unstructured":"\u2022 Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478:64\u20139. This study reported mutations of genes involved in RNA splicing in diverse myeloid malignancies.","journal-title":"Nature"},{"key":"184_CR40","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2011-01-331678","volume":"118","author":"T Klampfl","year":"2011","unstructured":"\u2022\u2022 Klampfl T, Harutyunyan A, Berg T, et al. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood. 2011;118:167\u201376. Investigation of chromosomal aberrations in MPN that identified commonly affected chromosomal regions and lesions that associated with disease progression.","journal-title":"Blood"},{"key":"184_CR41","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/leu.2010.99","volume":"24","author":"R Jager","year":"2010","unstructured":"Jager R, Gisslinger H, Passamonti F, et al. Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia. 2010;24:1290\u20138.","journal-title":"Leukemia"},{"key":"184_CR42","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri747","volume":"2","author":"K Georgopoulos","year":"2002","unstructured":"Georgopoulos K. Haematopoietic cell-fate decisions, chromatin regulation and ikaros. Nat Rev Immunol. 2002;2:162\u201374.","journal-title":"Nat Rev Immunol"},{"key":"184_CR43","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/10428190801993462","volume":"49","author":"G Kano","year":"2008","unstructured":"Kano G, Morimoto A, Takanashi M, et al. Ikaros dominant negative isoform (Ik6) induces IL-3-independent survival of murine pro-B lymphocytes by activating JAK-STAT and up-regulating Bcl-xl levels. Leuk Lymphoma. 2008;49:965\u201373.","journal-title":"Leuk Lymphoma"},{"key":"184_CR44","first-page":"8820","volume":"61","author":"AH Banham","year":"2001","unstructured":"Banham AH, Beasley N, Campo E, et al. The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res. 2001;61:8820\u20139.","journal-title":"Cancer Res"},{"key":"184_CR45","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/gcc.1127","volume":"31","author":"MD Odero","year":"2001","unstructured":"Odero MD, Carlson K, Calasanz MJ, et al. Identification of new translocations involving ETV6 in hematologic malignancies by fluorescence in situ hybridization and spectral karyotyping. Gene Chromosome Cancer. 2001;31:134\u201342.","journal-title":"Gene Chromosome Cancer"},{"key":"184_CR46","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.semcancer.2005.01.008","volume":"15","author":"SK Bohlander","year":"2005","unstructured":"Bohlander SK. ETV6: a versatile player in leukemogenesis. Semin Cancer Biol. 2005;15:162\u201374.","journal-title":"Semin Cancer Biol"},{"key":"184_CR47","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1128\/MCB.02089-07","volume":"28","author":"M Truscott","year":"2008","unstructured":"Truscott M, Harada R, Vadnais C, et al. p110 CUX1 cooperates with E2F transcription factors in the transcriptional activation of cell cycle-regulated genes. Mol Cell Biol. 2008;28:3127\u201338.","journal-title":"Mol Cell Biol"},{"key":"184_CR48","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1093\/nar\/gks041","volume":"40","author":"C Vadnais","year":"2012","unstructured":"Vadnais C, Davoudi S, Afshin M, et al. CUX1 transcription factor is required for optimal ATM\/ATR-mediated responses to DNA damage. Nucleic Acids Res. 2012;40:4483\u201395.","journal-title":"Nucleic Acids Res"},{"key":"184_CR49","doi-asserted-by":"crossref","first-page":"9492","DOI":"10.1158\/0008-5472.CAN-05-4230","volume":"66","author":"C Cadieux","year":"2006","unstructured":"Cadieux C, Fournier S, Peterson AC, et al. Transgenic mice expressing the p75 CCAAT-displacement protein\/Cut homeobox isoform develop a myeloproliferative disease-like myeloid leukemia. Cancer Res. 2006;66:9492\u2013501.","journal-title":"Cancer Res"},{"key":"184_CR50","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2003-09-3074","volume":"103","author":"H Harada","year":"2004","unstructured":"Harada H, Harada Y, Niimi H, et al. High incidence of somatic mutations in the AML1\/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood. 2004;103:2316\u201324.","journal-title":"Blood"},{"key":"184_CR51","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/ajh.23309","volume":"87","author":"JD Milosevic","year":"2012","unstructured":"\u2022 Milosevic JD, Puda A, Malcovati L, et al. Clinical significance of genetic aberrations in secondary acute myeloid leukemia. Am J Hematol. 2012;87:1010\u20136. This study compared genetic aberrations occurring in secondary and de novo AML and identified mutant TP53 as an independent adverse prognostic factor for overall survival in secondary AML.","journal-title":"Am J Hematol"},{"key":"184_CR52","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1084\/jem.20120521","volume":"210","author":"JS Jutzi","year":"2013","unstructured":"\u2022 Jutzi JS, Bogeska R, Nikoloski G, et al. MPN patients harbor recurrent truncating mutations in transcription factor NF-E2. J Exp Med. 2013;210:1003\u201319. This study reported mutations in nuclear factor erythroid 2 in MPN patients.","journal-title":"J Exp Med"},{"key":"184_CR53","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/blood-2009-11-254664","volume":"116","author":"W Wang","year":"2010","unstructured":"Wang W, Schwemmers S, Hexner EO, Pahl HL. AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2. Blood. 2010;116:254\u201366.","journal-title":"Blood"},{"key":"184_CR54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1182\/blood-2012-11-463257","volume":"122","author":"K Aumann","year":"2013","unstructured":"Aumann K, Frey AV, May AM, et al. Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates prefibrotic primary myelofibrosis from essential thrombocythemia. Blood. 2013;122:93\u20139.","journal-title":"Blood"},{"key":"184_CR55","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1084\/jem.20110540","volume":"209","author":"KB Kaufmann","year":"2012","unstructured":"Kaufmann KB, Grunder A, Hadlich T, et al. A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. J Exp Med. 2012;209:35\u201350.","journal-title":"J Exp Med"},{"key":"184_CR56","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrc3343","volume":"12","author":"AH Shih","year":"2012","unstructured":"Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer. 2012;12:599\u2013612.","journal-title":"Nat Rev Cancer"},{"key":"184_CR57","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","volume":"23","author":"A Tefferi","year":"2009","unstructured":"Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009;23:905\u201311.","journal-title":"Leukemia"},{"key":"184_CR58","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1126\/science.1170116","volume":"324","author":"M Tahiliani","year":"2009","unstructured":"Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324:930\u20135.","journal-title":"Science"},{"key":"184_CR59","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nature09586","volume":"468","author":"M Ko","year":"2010","unstructured":"Ko M, Huang Y, Jankowska AM, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010;468:839\u201343.","journal-title":"Nature"},{"key":"184_CR60","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/leu.2010.113","volume":"24","author":"A Tefferi","year":"2010","unstructured":"Tefferi A, Lasho TL, Abdel-Wahab O, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia. 2010;24:1302\u20139.","journal-title":"Leukemia"},{"key":"184_CR61","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/leu.2010.77","volume":"24","author":"A Pardanani","year":"2010","unstructured":"Pardanani A, Lasho TL, Finke CM, et al. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia. 2010;24:1146\u201351.","journal-title":"Leukemia"},{"key":"184_CR62","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","volume":"18","author":"ME Figueroa","year":"2010","unstructured":"Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18:553\u201367.","journal-title":"Cancer Cell"},{"key":"184_CR63","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","volume":"17","author":"PS Ward","year":"2010","unstructured":"Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17:225\u201334.","journal-title":"Cancer Cell"},{"key":"184_CR64","doi-asserted-by":"crossref","first-page":"11735","DOI":"10.1074\/jbc.M106590200","volume":"277","author":"T Yokochi","year":"2002","unstructured":"Yokochi T, Robertson KD. Preferential methylation of unmethylated DNA by Mammalian de novo DNA methyltransferase Dnmt3a. J Biol Chem. 2002;277:11735\u201345.","journal-title":"J Biol Chem"},{"key":"184_CR65","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","volume":"363","author":"TJ Ley","year":"2010","unstructured":"Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363:2424\u201333.","journal-title":"N Engl J Med"},{"key":"184_CR66","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/leu.2011.77","volume":"25","author":"F Stegelmann","year":"2011","unstructured":"Stegelmann F, Bullinger L, Schlenk RF, et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia. 2011;25:1217\u20139.","journal-title":"Leukemia"},{"key":"184_CR67","doi-asserted-by":"crossref","first-page":"17588","DOI":"10.1074\/jbc.M512616200","volume":"281","author":"YS Cho","year":"2006","unstructured":"Cho YS, Kim EJ, Park UH, et al. Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor. J Biol Chem. 2006;281:17588\u201398.","journal-title":"J Biol Chem"},{"key":"184_CR68","doi-asserted-by":"crossref","first-page":"9113","DOI":"10.1074\/jbc.M708205200","volume":"283","author":"K Kim","year":"2008","unstructured":"Kim K, Choi J, Heo K, et al. Isolation and characterization of a novel H1.2 complex that acts as a repressor of p53-mediated transcription. J Biol Chem. 2008;283:9113\u201326.","journal-title":"J Biol Chem"},{"key":"184_CR69","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","volume":"22","author":"O Abdel-Wahab","year":"2012","unstructured":"Abdel-Wahab O, Adli M, LaFave LM, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell. 2012;22:180\u201393.","journal-title":"Cancer Cell"},{"key":"184_CR70","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3324\/haematol.2011.045591","volume":"96","author":"BL Stein","year":"2011","unstructured":"Stein BL, Williams DM, O'Keefe C, et al. Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. Haematologica. 2011;96:1462\u20139.","journal-title":"Haematologica"},{"key":"184_CR71","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2011-07-367243","volume":"119","author":"J Score","year":"2012","unstructured":"\u2022 Score J, Hidalgo-Curtis C, Jones AV, et al. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic\/myeloproliferative neoplasms. Blood. 2012;119:1208\u201313. Inactivating mutations in polycomb repressive complex 2 members were reported in MPN and MDS\/MPN patients.","journal-title":"Blood"},{"key":"184_CR72","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ajh.22257","volume":"87","author":"A Puda","year":"2012","unstructured":"\u2022 Puda A, Milosevic JD, Berg T, et al. Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. Am J Hematol. 2012;87:245\u201350. This study reported frequent deletions of JARID2 and suggested that mutations in polycomb repressive complex 2 components are important for leukemic transformation.","journal-title":"Am J Hematol"},{"key":"184_CR73","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.stem.2010.08.002","volume":"7","author":"M Sauvageau","year":"2010","unstructured":"Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell. 2010;7:299\u2013313.","journal-title":"Cell Stem Cell"},{"key":"184_CR74","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature09784","volume":"469","author":"R Margueron","year":"2011","unstructured":"Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature. 2011;469:343\u20139.","journal-title":"Nature"},{"key":"184_CR75","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1038\/leu.2008.233","volume":"22","author":"R Kralovics","year":"2008","unstructured":"Kralovics R. Genetic complexity of myeloproliferative neoplasms. Leukemia. 2008;22:1841\u20138.","journal-title":"Leukemia"},{"key":"184_CR76","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2005-11-009605","volume":"108","author":"R Kralovics","year":"2006","unstructured":"Kralovics R, Teo SS, Li S, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006;108:1377\u201380.","journal-title":"Blood"},{"key":"184_CR77","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.exphem.2006.11.012","volume":"35","author":"RH Nussenzveig","year":"2007","unstructured":"Nussenzveig RH, Swierczek SI, Jelinek J, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol. 2007;35:32\u20138.","journal-title":"Exp Hematol"},{"key":"184_CR78","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMc0910063","volume":"362","author":"A Green","year":"2010","unstructured":"Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med. 2010;362:369\u201370.","journal-title":"N Engl J Med"},{"key":"184_CR79","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.coi.2010.06.007","volume":"22","author":"I Beerman","year":"2010","unstructured":"Beerman I, Maloney WJ, Weissmann IL, Rossi DJ. Stem cells and the aging hematopoietic system. Curr Opin Immunol. 2010;22:500\u20136.","journal-title":"Curr Opin Immunol"},{"key":"184_CR80","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1073\/pnas.1000834107","volume":"107","author":"I Beerman","year":"2010","unstructured":"Beerman I, Bhattacharya D, Zandi S, et al. Functionally distinct hematopoietic stem cells modulate hematopoietic lineage potential during aging by a mechanism of clonal expansion. Proc Natl Acad Sci U S A. 2010;107:5465\u201370.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"184_CR81","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ajhg.2011.12.009","volume":"90","author":"LA Forsberg","year":"2012","unstructured":"\u2022\u2022 Forsberg LA, Rasi C, Razzaghian HR, et al. Age-related somatic structural changes in the nuclear genome of human blood cells. Am J Hum Genet. 2012;90:217\u201328. This study found in a cohort of twins an accumulation of somatic structural variants with age and somatic changes that are seen in myeloid malignancies.","journal-title":"Am J Hum Genet"},{"key":"184_CR82","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/ng.2270","volume":"44","author":"KB Jacobs","year":"2012","unstructured":"\u2022\u2022 Jacobs KB, Yeager M, Zhou W, et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet. 2012;44:651\u20138. As in reference 83, this study reported that the frequency of somatic chromosomal changes increases with age and that these lesions correlated with genomic aberrations described for myeloid malignancies.","journal-title":"Nat Genet"},{"key":"184_CR83","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/ng.2271","volume":"44","author":"CC Laurie","year":"2012","unstructured":"\u2022\u2022 Laurie CC, Laurie CA, Rice K, et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet. 2012;44:642\u201350. As in reference 82, this study reported that the frequency of somatic chromosomal changes increases with age and that these lesions correlated with genomic aberrations described for myeloid malignancies.","journal-title":"Nat Genet"},{"key":"184_CR84","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/ng.2413","volume":"44","author":"L Busque","year":"2012","unstructured":"\u2022\u2022 Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012;44:1179\u201381. This study found somatic mutations in TET2 in elderly individuals with clonal hematopoiesis.","journal-title":"Nat Genet"},{"key":"184_CR85","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/leu.2011.253","volume":"26","author":"A Tefferi","year":"2012","unstructured":"Tefferi A, Jimma T, Sulai NH, et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia. 2012;26:475\u201380.","journal-title":"Leukemia"},{"key":"184_CR86","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMc1012718","volume":"364","author":"A Harutyunyan","year":"2011","unstructured":"\u2022 Harutyunyan A, Klampfl T, Cazzola M, Kralovics R. p53 lesions in leukemic transformation. N Engl J Med. 2011;364:488\u201390. P53-related aberrations were associated with post-MPN AML, which suggests that the p53 pathway is important for leukemic transformation.","journal-title":"N Engl J Med"},{"key":"184_CR87","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM198102193040801","volume":"304","author":"PD Berk","year":"1981","unstructured":"Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med. 1981;304:441\u20137.","journal-title":"N Engl J Med"},{"key":"184_CR88","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","volume":"29","author":"M Bjorkholm","year":"2011","unstructured":"Bjorkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol. 2011;29:2410\u20135.","journal-title":"J Clin Oncol"},{"key":"184_CR89","doi-asserted-by":"crossref","unstructured":"\u2022 Tefferi A, Rumi E, Finazzi G, et al.: Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 2013. This study encompassed seven centers and investigated survival and leukemic transformation in polycythemia vera patients.","DOI":"10.1038\/leu.2013.163"},{"key":"184_CR90","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","volume":"29","author":"JJ Kiladjian","year":"2011","unstructured":"Kiladjian JJ, Chevret S, Dosquet C, et al. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol. 2011;29:3907\u201313.","journal-title":"J Clin Oncol"},{"key":"184_CR91","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1179\/102453308X316022","volume":"13","author":"F Radaelli","year":"2008","unstructured":"Radaelli F, Onida F, Rossi FG, et al. Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution. Hematology. 2008;13:195\u2013202.","journal-title":"Hematology"},{"key":"184_CR92","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1586\/era.11.10","volume":"11","author":"JL Spivak","year":"2011","unstructured":"Spivak JL, Hasselbalch H. Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders. Expert Rev Anticancer Ther. 2011;11:403\u201314.","journal-title":"Expert Rev Anticancer Ther"},{"key":"184_CR93","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.tig.2011.12.002","volume":"28","author":"HC Reinhardt","year":"2012","unstructured":"Reinhardt HC, Schumacher B. The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet. 2012;28:128\u201336.","journal-title":"Trends Genet"},{"key":"184_CR94","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V91.2.616","volume":"91","author":"Y Sterkers","year":"1998","unstructured":"Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood. 1998;91:616\u201322.","journal-title":"Blood"},{"key":"184_CR95","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/leu.2008.280","volume":"22","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia. 2008;22:1990\u20138.","journal-title":"Leukemia"},{"key":"184_CR96","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","volume":"112","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112:3065\u201372.","journal-title":"Blood"},{"key":"184_CR97","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","volume":"27","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27:5418\u201324.","journal-title":"J Clin Oncol"},{"key":"184_CR98","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00063030-200115070-00001","volume":"15","author":"A Kozlowski","year":"2001","unstructured":"Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs. 2001;15:419\u201329.","journal-title":"BioDrugs"},{"key":"184_CR99","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/leu.2010.120","volume":"24","author":"JJ Kiladjian","year":"2010","unstructured":"Kiladjian JJ, Masse A, Cassinat B, et al. Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia. 2010;24:1519\u201323.","journal-title":"Leukemia"},{"key":"184_CR100","doi-asserted-by":"crossref","unstructured":"\u2022 Quintas-Cardama A, Abdel-Wahab O, Manshouri T, et al.: Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a. Blood 2013. This follow-up study of a phase II trial with pegylated interferon alpha-2a focused on the molecular analysis of the interferon treated MPN patients and suggested that genetic aberrations might influence drug response.","DOI":"10.1182\/blood-2012-07-442012"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-013-0184-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-013-0184-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-013-0184-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T14:18:57Z","timestamp":1647008337000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-013-0184-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,5]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["184"],"URL":"https:\/\/doi.org\/10.1007\/s11899-013-0184-z","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,5]]}}}